ReviewHuman vaccines & immunotherapeutics2024
Opportunities and challenges for human papillomavirus vaccination in China.
Review in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 32 citations in OpenAlex.
- Prevention is better than cure: Awareness and acceptance of the HPV vaccine for condyloma acuminata (CA) among college students who self-report no sexual experience.Human vaccines & immunotherapeutics · 2026Article
- A pilot evaluation of ChatGPT-4o-assisted hypothesis generation for exploring potential links between fungal biology and cervical cancer.Antonie van Leeuwenhoek · 2026Article
- Article
- HPV epidemiologic study in Bengbu, China, involving 123,808 women, 2014-2023.Virology journal · 2026Article
- Incidence, recurrence, and determinants of sexually transmitted infections among people with HIV: a multicenter cohort study in China, 2010-2024, with implications for integrated HIV-STI prevention across the Western Pacific.The Lancet regional health. Western Pacific · 2026Article
- Immunogenicity of anVaccines · 2026Article
- Global and Regional Diagnostic Results of Progress Toward Cervical Cancer Elimination, According to the WHO Strategy: A Systematic Literature Review with Narrative SynthesisDiagnostics (Basel, Switzerland) · 2026Review
- Review
- Factors influencing Chongqing nurses' HPV vaccination: a cross-sectional survey based on the 5C model.Frontiers in public health · 2026Article
- Factors influencing HPV vaccination intention and uptake behaviors among medical students based on the health belief model and vaccine hesitancy theory: a cross-sectional study.Frontiers in public health · 2026Article
- Limited discriminant validity of health belief and 3C models in high HPV vaccine coverage settings: the moderating role ofFrontiers in public health · 2026Article
- Addressing male HPV vaccination in China: A narrative review of challenges and opportunities.Human vaccines & immunotherapeutics · 2025Review
- Stability study of recombinant 9-valent human papillomavirus vaccine based onHuman vaccines & immunotherapeutics · 2025Article
- Investigating the impact of oxygen concentration on the assembly of human papillomavirus virus like particles.Scientific reports · 2025Article
- Human papillomavirus vaccination willingness and influencing factors among women in China: A systematic review and meta-analysis.Preventive medicine reports · 2025Review
- How delays in seeking medical care for cervical cancer patients are affected by their health-seeking behaviour: a qualitative study.BMC public health · 2025Article
- Literature Review and Policy Recommendations for Single-Dose HPV Vaccination Schedule in China: Opportunities and Challenges.Vaccines · 2025Review
- Article
- Monitoring the presence of human papillomavirus in public areas indicates non-sexual transmission of the virus and environmental risk.BMC public health · 2025Article
- Benefits and challenges of cervical cancer screening since the implementation of the 'two cancer' screening programme in China: findings from Shangyu, Zhejiang in 2019-23.Journal of global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current estimates of the HPV infection rate in China vary by geographic region (9.6-23.6%), with two age peaks in prevalence in women ≤20-25 years of age and 50-60 years of age. HPV-16, 52 and 58 are the most commonly-detected HPV genotypes in the Chinese population. In China, five HPV vaccines are licensed and several others are undergoing clinical trials. Multiple RCTs have shown the efficacy and safety of the bvHPV (Cervarix),
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.